Roche’s Tecentriq/Avastin combo gets liver cancer nodThe FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – Share XRoche’s Tecentriq/Avastin combo gets liver cancer nodhttps://pharmaphorum.com/news/roches-tecentriq-avastin-combo-gets-liver-cancer-nod/
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerAfter a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi Share XAZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerhttps://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
Lilly gets fifth use for Cyramza with FDA liver cancer nodEli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line Share XLilly gets fifth use for Cyramza with FDA liver cancer nodhttps://pharmaphorum.com/news/lilly-gets-fifth-use-for-cyramza-with-fda-liver-cancer-nod/
Exelixis’ Cabometyx approved in second-line liver cancer in USExelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a Share XExelixis’ Cabometyx approved in second-line liver cancer in UShttps://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
